Thanks Kenbe. The Prescription for Change Th

Thanks Kenbe.
The Prescription for Change
The need for compounding pharmacy services will continue to be vital to the delivery of quality healthcare and demand is expected to grow (I have stated this several times in previous posts. Compound pharmacy is here to stay).
. The industry is changing and industry owners need to increase their investments in order to improve operations (From everything we have read, Mr. Schneiderman is ahead of the curve in this area. TN Apothecary and Jungle Jim are two examples of his "investments"). Industry and regulatory pressures will force smaller inefficient compound pharmacies to sell, merge or invest ( Q2 & Q3 10Qs have demonstrated SCRC/MAP is not a small inefficient compound pharmacy).

It's important to remember even though MAP is the driver for SCRC's revenues now, it is only one of several revenue streams in SCRC business model. It will interesting to hear what Mr. Schneiderman has to say about the future of SCRC on the December 3rd conference call.